For background on how FDA enforcement is reshaping the research peptide supply chain, explore our Industry & Regulatory section in the Research Library.
Peptide Sciences operated for over a decade as one of the most recognized names in the research peptide supply market. In early 2026, it stopped taking orders. No formal announcement explained the timing, but the pattern was familiar to anyone watching the industry: escalating FDA enforcement, compounding pharmacy restrictions, and the operational cost of maintaining research-grade documentation at scale had made the business model untenable. Peptide Sciences wasn’t the first supplier to exit and won’t be the last.
What that exit created was a gap. Researchers who had built sourcing relationships around a single supplier suddenly needed alternatives, and the question most of them were asking wasn’t philosophical. It was practical: where do you go, and how do you know the replacement is legitimate?
The answer isn’t to find a supplier that looks like Peptide Sciences. It’s to apply stricter criteria than most researchers were using before. The shutdown exposed a structural problem in how researchers evaluated vendors. Price, product range, and name recognition drove most sourcing decisions. Third-party COA documentation, HPLC verification, and batch-level traceability were often assumed rather than confirmed. The suppliers still operating in 2026 are the ones that built their quality infrastructure before enforcement pressure required it, not in response to it.
The practical checklist for evaluating a replacement supplier is straightforward. Every compound should come with a third-party certificate of analysis showing HPLC purity of 98% or higher and mass spectrometry confirmation of the correct molecular weight. The COA should be batch-specific, not generic. The supplier should be willing to provide documentation on request rather than making it difficult to find. And the website should make research-use-only framing explicit throughout, not buried in a footer disclaimer.
BioStrata supplies research-grade compounds with full third-party COA documentation for every batch. BPC-157 is one of the most actively researched peptides in the current literature and is available in 10mg research-grade format. The full compound catalog is at the BioStrata shop.
FDA Enforcement on Peptide Companies Is Accelerating in 2026 — Peptide Drug Summit
FDA Peptide Ban Lifted: 14 Peptides Reclassified in 2026 — Peptide Journal